Immunogenic compositions to treat and prevent microbial infections
Inventors
Sei, Clara J. • Daum, Luke T. • Fischer, Gerald W.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12331083-B2
Publication Date
2025-06-17
Expiration Date
Abstract
The invention relates to composite antigens comprising a peptide with contiguous amino acid sequence derived from a plurality of antigenic epitopes of one or more pathogens that induces an immune response in a mammal that is protective against infection by the one or more pathogens. In addition. The invention also relates to antibodies to composite antigens of the invention and to methods of administering vaccines comprising antigens or vaccines of antibodies for treating and/or preventing an infection.
Core Innovation
The invention relates to immunogenic peptide(s) that contain a plurality of microbial epitopes. The plurality comprises one or more epitopes of a Mycobacterium and one or more epitopes of an influenza virus, and the plurality is contained in a contiguous peptide sequence. The immunogenic peptide contains one or more sequences selected from specified SEQ ID NOs.
The invention also provides immunogenic peptides in which the influenza virus epitope component is defined by neuraminidase protein epitopes or matrix protein epitopes, while the Mycobacterium component is defined by peptidoglycan epitopes or heat shock protein epitopes. In each case, the plurality of microbial epitopes is contained in a contiguous peptide sequence, and the immunogenic peptide includes one or more sequences selected from specified SEQ ID NO sets.
The invention further includes an immunogenic peptide defined by a contiguous sequence selected from SEQ ID NOs 113 and 114. In this context, the immunogenic peptide is presented as a pharmaceutical composition together with pharmaceutically acceptable diluents, excipients, or carriers, and optionally further comprises an adjuvant selected from enumerated adjuvant types.
Claims Coverage
The document provides four independent claims, each centered on an immunogenic peptide defined by contiguous peptide sequence organization and inclusion of specified microbial epitopes via selected SEQ ID NOs, with claim-dependent refinement regarding positional placement of T cell-stimulating epitope(s) and optional adjuvant selection.
Contiguous composite peptide with Mycobacterium and influenza epitopes
An immunogenic peptide containing a plurality of microbial epitopes, wherein the plurality comprises one or more epitopes of a Mycobacterium and one or more epitopes of an influenza virus wherein the plurality is contained in a contiguous peptide sequence, and the immunogenic peptide contains one or more sequences selected from the group consisting of specified SEQ ID NOs.
Contiguous peptide with Mycobacterium peptidoglycan and influenza neuraminidase epitopes
An immunogenic peptide containing a plurality of microbial epitopes, wherein the plurality comprises one or more epitopes of peptidoglycan of a Mycobacterium and one or more epitopes of a neuraminidase protein of an influenza virus wherein the plurality is contained in a contiguous peptide sequence, and the immunogenic peptide contains one or more sequences selected from the group consisting of specified SEQ ID NOs.
Contiguous peptide with Mycobacterium heat shock protein and influenza matrix protein epitopes
An immunogenic peptide containing a plurality of microbial epitopes, wherein the plurality comprises one or more epitopes of a heat shock protein of a Mycobacterium and one or more epitopes of a matrix protein of an influenza virus wherein the plurality is contained in a contiguous peptide sequence, and the immunogenic peptide contains one or more sequences selected from the group consisting of specified SEQ ID NOs.
Pharmaceutical composition with contiguous sequence selected from SEQ ID NOs 113 and 114
An immunogenic peptide containing as a contiguous sequence a sequence selected from the group consisting of SEQ ID NOs. 113 and 114.
Across the independent claims, the core claimed subject matter is an immunogenic peptide whose microbial epitopes from Mycobacterium and influenza virus are arranged in a contiguous peptide sequence, and whose specific sequence identity is constrained by inclusion of one or more specified SEQ ID NOs; one independent claim is directed to a particular contiguous sequence selection used in a pharmaceutical composition context.
Stated Advantages
Documented Applications
No documented applications found
Interested in licensing this patent?